Eiger BioPharmaceuticals (STU:72C) Forward Dividend Yield %: 0.00% (As of Jul. 09, 2026)


STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals Forward Dividend Yield %?

Eiger BioPharmaceuticals STU:72C 10 Forward Dividend Yield % is 0.00% as of Jul. 09, 2026. GuruFocus rates STU:72C with a GF Score™ of 10/100.

As of today (2026-07-09), the Forward Annual Dividend Yield of Eiger BioPharmaceuticals is 0.00%.

As of today (2026-07-09), the Trailing Annual Dividend Yield of Eiger BioPharmaceuticals is 0.00%.

STU:72C's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.3
* Ranked among companies with meaningful Forward Dividend Yield % only.

Eiger BioPharmaceuticals's Dividends per Share for the six months ended in Dec. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Eiger BioPharmaceuticals  (STU:72C) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Eiger BioPharmaceuticals Forward Dividend Yield % Related Terms

STU:72C vs EDSA, SIGY, EVLO: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eiger BioPharmaceuticals Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Forward Dividend Yield % falls into.


STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiger BioPharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Eiger BioPharmaceuticals (STU:72C) has a Forward Dividend Yield % of 0.00% as of Jul. 09, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Eiger BioPharmaceuticals and its competitors.
Is Eiger BioPharmaceuticals' Forward Dividend Yield % too high?
Eiger BioPharmaceuticals' current Forward Dividend Yield % is 0.00%. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' Forward Dividend Yield % compare to EDSA and SIGY?
Eiger BioPharmaceuticals' Forward Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Forward Dividend Yield % is 1.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.30, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Eiger BioPharmaceuticals and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiger BioPharmaceuticals's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Forward Dividend Yield % is 0.00% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price